188 related articles for article (PubMed ID: 31879018)
1. [Thyroid dysfunctions secondary to cancer immunotherapy].
Cugnet Anceau C; Abeillon J; Maillet D; Borson-Chazot F; Disse E
Bull Cancer; 2020 Feb; 107(2):262-271. PubMed ID: 31879018
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Lee H; Hodi FS; Giobbie-Hurder A; Ott PA; Buchbinder EI; Haq R; Tolaney S; Barroso-Sousa R; Zhang K; Donahue H; Davis M; Gargano ME; Kelley KM; Carroll RS; Kaiser UB; Min L
Cancer Immunol Res; 2017 Dec; 5(12):1133-1140. PubMed ID: 29079654
[TBL] [Abstract][Full Text] [Related]
3. Expert opinion on thyroid complications in immunotherapy.
Illouz F; Drui D; Caron P; Do Cao C
Ann Endocrinol (Paris); 2018 Oct; 79(5):555-561. PubMed ID: 30126627
[TBL] [Abstract][Full Text] [Related]
4. Common thyroid disorders.
Sakiyama R
Am Fam Physician; 1988 Jul; 38(1):227-38. PubMed ID: 3293385
[No Abstract] [Full Text] [Related]
5. Thyroid dysfunctions secondary to cancer immunotherapy.
Chalan P; Di Dalmazi G; Pani F; De Remigis A; Corsello A; Caturegli P
J Endocrinol Invest; 2018 Jun; 41(6):625-638. PubMed ID: 29238906
[TBL] [Abstract][Full Text] [Related]
6. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
8. [Subclinical thyroid dysfunction].
Goichot B; Luca F
Presse Med; 2011 Dec; 40(12 Pt 1):1132-40. PubMed ID: 22115677
[TBL] [Abstract][Full Text] [Related]
9. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
Brilli L; Danielli R; Campanile M; Secchi C; Ciuoli C; Calabrò L; Pilli T; Cartocci A; Pacini F; Di Giacomo AM; Castagna MG
J Endocrinol Invest; 2021 Aug; 44(8):1719-1726. PubMed ID: 33367977
[TBL] [Abstract][Full Text] [Related]
10. [Autoimmune hypophysitis associated with new anti-cancer immunotherapies].
Jannin A; Merlen E; Do Cao C; Penel N
Bull Cancer; 2018 Mar; 105(3):275-280. PubMed ID: 29475597
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
13. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
Orlov S; Salari F; Kashat L; Walfish PG
J Clin Endocrinol Metab; 2015 May; 100(5):1738-41. PubMed ID: 25751110
[TBL] [Abstract][Full Text] [Related]
14. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.
Campredon P; Mouly C; Lusque A; Bigay-Game L; Bousquet E; Mazières J; Caron P
Presse Med; 2019 Apr; 48(4):e199-e207. PubMed ID: 31005502
[TBL] [Abstract][Full Text] [Related]
15. [CME: Thyrotoxicosis and Thyroiditis].
Slahor L
Praxis (Bern 1994); 2018; 107(22):1187-1192. PubMed ID: 30376773
[TBL] [Abstract][Full Text] [Related]
16. Thyroid diseases in elderly.
Faggiano A; Del Prete M; Marciello F; Marotta V; Ramundo V; Colao A
Minerva Endocrinol; 2011 Sep; 36(3):211-31. PubMed ID: 22019751
[TBL] [Abstract][Full Text] [Related]
17. [Current questions of thyroid diseases in childhood].
Ilyés I
Orv Hetil; 2011 Apr; 152(16):617-27. PubMed ID: 21454178
[TBL] [Abstract][Full Text] [Related]
18. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
19. Management of thyroid disorders.
McGuinness ME; Talbert RL
Am Pharm; 1994 Dec; NS34(12):36-47. PubMed ID: 7856507
[No Abstract] [Full Text] [Related]
20. Over-the-counter-drug-induced thyroid disorders.
Hoang TD; Mai VQ; Clyde PW; Shakir MK
Endocr Pract; 2013; 19(2):268-74. PubMed ID: 23529350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
